Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.39 |
| ▸ | LPL | P06858 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307081 | 0.77 | ENPP2 (0.47) | ENPP2LPLLIPGCA4CA6 | |
| SCHEMBL16576635 | 0.77 | LPL (0.42) | ENPP2LPLLIPGCA2CA1 | |
| SCHEMBL7055234 | 0.76 | ESR2 (0.48) | CA2CA1CA4CA5ACA14 | |
| SCHEMBL8353941 | 0.74 | L3MBTL1 (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL14710296 | 0.74 | SLC6A4 (0.37) | SLC6A2SLC6A4 | |
| SCHEMBL3615305 | 0.74 | SLC6A4 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL4275 | 0.74 | ALDH1A1 (0.38) | SLC6A2SLC6A4 | |
| SCHEMBL5645623 | 0.74 | SLC6A2 (0.37) | SLC6A2SLC6A4 | |
| SCHEMBL7704791 | 0.74 | SLC6A3 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL1371770 | 0.73 | MAOA (0.60) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| CN-108602770-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| WO-2015091937-A1 | OXINDOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE IN THE TREATMENT OF AMPK-RELATED DISEASES | SANOFI (FR) | 2015-06-25 | — | — | WO | disclosed |
| EP-2886541-A1 | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases | SANOFI (FR) | 2015-06-24 | — | — | EP | disclosed |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | ENPP2 2882/4885LPL 2234/4885LIPG 2402/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | ENPP2 2882/4885LPL 2804/4885LIPG 2297/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | ENPP2 1725/4885LPL 2520/4885LIPG 1949/4885 |
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | ENPP2 1418/4885LPL 4460/4885LIPG 4641/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | ENPP2 1572/4885LPL 3192/4885LIPG 3040/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | ENPP2 1418/4885LPL 4460/4885LIPG 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.